Is there any role left for p210-derived peptide vaccines in chronic myeloid leukemia?
Bocchia
Monica
M
D000951:Antigens, Neoplasm / Q000627:therapeutic use; D019496:Cancer Vaccines / Q000627:therapeutic use*; D016044:Fusion Proteins, bcr-abl / Q000276:immunology* / Q000627:therapeutic use; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*; D010446:Peptide Fragments / Q000276:immunology / Q000627:therapeutic use
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D010446:Peptide Fragments; D016044:Fusion Proteins, bcr-abl